(1)
Positive first results from the complete dose-finding part of a phase Ib/II study of tumor-agnostic NBTXR3 (PEP503) activated by radiotherapy with concurrent chemotherapy for patients with rectal cancer show that intratumoral injection of the product candidate was feasible and it was well tolerated at all dose levels
An injection procedure-related dose-limiting toxicity of urinary tract infection was observed in the study, however there were no observed adverse events or severe adverse events associated with NBTXR3
More than 70% of patients showed objective tumor response after concurrent chemoradiation
Approximately 90% of patients underwent total mesorectal excision (surgery), and 17.6% achieved pathological complete response
Market cap of 17 Education & Technology Group Inc [YQ] reaches 2 27B – now what? dbtnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from dbtnews.com Daily Mail and Mail on Sunday newspapers.
/PRNewswire/ DocuSign, Inc. (Nasdaq: DOCU) today announced that it has closed its offering of 0% convertible senior notes due 2024 (the "notes") for gross.
Playtika has successfully raised just shy of $1.88 billion through its Initial Public Offering.
These shares begin trading on the Nasdaq Global Select Market today under the symbol PLTK with the offering due to close on Wednesday, January 20.
The sale consisted of 18.5 million shares of common stock from Playtika, while the other 51 million were sold by an existing stockholder. Playtika will not receive any of the proceeds from sales of the latter.
As previously reported, the proceeds Playtika raised will be used for a mix of general corporate expenses, the potential repayment of loans, and future investments and acquisitions.
Playtika s journey to an IPO began back in 2019, when China-based Giant Network Group gave up on acquiring the mobile firm after regulators prevented repeated attempts.